145 related articles for article (PubMed ID: 21282974)
1. Bortezomib treatment causes remission in a Ph+ALL patient and reveals FoxO as a theranostic marker.
Dewar R; Chen ST; Yeckes-Rodin H; Miller K; Khosravi-Far R
Cancer Biol Ther; 2011 Mar; 11(6):552-8. PubMed ID: 21282974
[TBL] [Abstract][Full Text] [Related]
2. Proteasome inhibition causes regression of leukemia and abrogates BCR-ABL-induced evasion of apoptosis in part through regulation of forkhead tumor suppressors.
Jagani Z; Song K; Kutok JL; Dewar MR; Melet A; Santos T; Grassian A; Ghaffari S; Wu C; Yeckes-Rodin H; Ren R; Miller K; Khosravi-Far R
Cancer Res; 2009 Aug; 69(16):6546-55. PubMed ID: 19654305
[TBL] [Abstract][Full Text] [Related]
3. Out foxing bcr-abl.
Claxton DF
Cancer Biol Ther; 2011 Apr; 11(8):769-70. PubMed ID: 21358259
[No Abstract] [Full Text] [Related]
4. Bortezomib and flavopiridol interact synergistically to induce apoptosis in chronic myeloid leukemia cells resistant to imatinib mesylate through both Bcr/Abl-dependent and -independent mechanisms.
Dai Y; Rahmani M; Pei XY; Dent P; Grant S
Blood; 2004 Jul; 104(2):509-18. PubMed ID: 15039284
[TBL] [Abstract][Full Text] [Related]
5. Haematological complete remission by ponatinib and bortezomib in a patient with relapsed, Ph⁺ pre-B acute lymphoblastic leukaemia.
Robinson S; Levy Y; Maisel C; Tong AW
BMJ Case Rep; 2014 Apr; 2014():. PubMed ID: 24729118
[TBL] [Abstract][Full Text] [Related]
6. [The anti-leukemic effects of imatinib, daunorubicin and bortezomib on two leukemia cell lines with Ph(+)].
Yang X; Yang L; Gong YP; Chang H; Zhou RQ; Xing HY; Zheng BH
Sichuan Da Xue Xue Bao Yi Xue Ban; 2010 Sep; 41(5):793-6. PubMed ID: 21302443
[TBL] [Abstract][Full Text] [Related]
7. The proteasome inhibitor bortezomib interacts synergistically with histone deacetylase inhibitors to induce apoptosis in Bcr/Abl+ cells sensitive and resistant to STI571.
Yu C; Rahmani M; Conrad D; Subler M; Dent P; Grant S
Blood; 2003 Nov; 102(10):3765-74. PubMed ID: 12893773
[TBL] [Abstract][Full Text] [Related]
8. Bortezomib induces apoptosis in primitive chronic myeloid leukemia cells including LTC-IC and NOD/SCID repopulating cells.
Heaney NB; Pellicano F; Zhang B; Crawford L; Chu S; Kazmi SM; Allan EK; Jorgensen HG; Irvine AE; Bhatia R; Holyoake TL
Blood; 2010 Mar; 115(11):2241-50. PubMed ID: 20068223
[TBL] [Abstract][Full Text] [Related]
9. Leukemia cell lines: in vitro models for the study of Philadelphia chromosome-positive leukemia.
Drexler HG; MacLeod RA; Uphoff CC
Leuk Res; 1999 Mar; 23(3):207-15. PubMed ID: 10071072
[TBL] [Abstract][Full Text] [Related]
10. Bortezomib and sphingosine kinase inhibitor interact synergistically to induces apoptosis in BCR/ABl+ cells sensitive and resistant to STI571 through down-regulation Mcl-1.
Li QF; Yan J; Zhang K; Yang YF; Xiao FJ; Wu CT; Wang H; Wang LS
Biochem Biophys Res Commun; 2011 Feb; 405(1):31-6. PubMed ID: 21195056
[TBL] [Abstract][Full Text] [Related]
11. Role of early anthracycline dose-intensity according to expression of Philadelphia chromosome/BCR-ABL rearrangements in B-precursor adult acute lymphoblastic leukemia.
Bassan R; Rohatiner AZ; Lerede T; Di Bona E; Rambaldi A; Pogliani E; Rossi G; Fabris P; Morandi S; Casula P; Carter M; Lambertenghi-Deliliers G; Lister TA; Barbui T
Hematol J; 2000; 1(4):226-34. PubMed ID: 11920195
[TBL] [Abstract][Full Text] [Related]
12. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome.
Druker BJ; Sawyers CL; Kantarjian H; Resta DJ; Reese SF; Ford JM; Capdeville R; Talpaz M
N Engl J Med; 2001 Apr; 344(14):1038-42. PubMed ID: 11287973
[TBL] [Abstract][Full Text] [Related]
13. HDAC1,2 inhibition and doxorubicin impair Mre11-dependent DNA repair and DISC to override BCR-ABL1-driven DSB repair in Philadelphia chromosome-positive B-cell precursor acute lymphoblastic leukemia.
Tharkar-Promod S; Johnson DP; Bennett SE; Dennis EM; Banowsky BG; Jones SS; Shearstone JR; Quayle SN; Min C; Jarpe M; Mosbruger T; Pomicter AD; Miles RR; Chen WY; Bhalla KN; Zweidler-McKay PA; Shrieve DC; Deininger MW; Chandrasekharan MB; Bhaskara S
Leukemia; 2018 Jan; 32(1):49-60. PubMed ID: 28579617
[TBL] [Abstract][Full Text] [Related]
14. Recent advancements of bortezomib in acute lymphocytic leukemia treatment.
Du XL; Chen Q
Acta Haematol; 2013; 129(4):207-14. PubMed ID: 23295437
[TBL] [Abstract][Full Text] [Related]
15. Dasatinib: a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia.
Steinberg M
Clin Ther; 2007 Nov; 29(11):2289-308. PubMed ID: 18158072
[TBL] [Abstract][Full Text] [Related]
16. Expression of CD25 is a specific and relatively sensitive marker for the Philadelphia chromosome (BCR-ABL1) translocation in pediatric B acute lymphoblastic leukemia.
Gaikwad AS; Donohue RE; Elghetany MT; Sheehan AM; Lu XY; Gramatges MM; McClain KL; Mistretta TA; Punia JN; Moore TJ; Goltsova T; Cubbage M; Curry CV
Int J Clin Exp Pathol; 2014; 7(9):6225-30. PubMed ID: 25337274
[TBL] [Abstract][Full Text] [Related]
17. Chimeric BCR-abl messenger RNA as a marker for minimal residual disease in patients transplanted for Philadelphia chromosome-positive acute lymphoblastic leukemia.
Gehly GB; Bryant EM; Lee AM; Kidd PG; Thomas ED
Blood; 1991 Jul; 78(2):458-65. PubMed ID: 2070081
[TBL] [Abstract][Full Text] [Related]
18. The mammalian target of rapamycin inhibitor RAD001 (everolimus) synergizes with chemotherapeutic agents, ionizing radiation and proteasome inhibitors in pre-B acute lymphocytic leukemia.
Saunders P; Cisterne A; Weiss J; Bradstock KF; Bendall LJ
Haematologica; 2011 Jan; 96(1):69-77. PubMed ID: 20952516
[TBL] [Abstract][Full Text] [Related]
19. Evidence for specific immune response against P210 BCR-ABL in long-term remission CML patients treated with interferon.
Oka T; Sastry KJ; Nehete P; Schapiro SJ; Guo JQ; Talpaz M; Arlinghaus RB
Leukemia; 1998 Feb; 12(2):155-63. PubMed ID: 9519777
[TBL] [Abstract][Full Text] [Related]
20. Combination therapy of BCR-ABL-positive B cell acute lymphoblastic leukemia by tyrosine kinase inhibitor dasatinib and c-JUN N-terminal kinase inhibition.
Xiao X; Liu P; Li D; Xia Z; Wang P; Zhang X; Liu M; Liao L; Jiao B; Ren R
J Hematol Oncol; 2020 Jun; 13(1):80. PubMed ID: 32552902
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
